PELP1 Suppression Inhibits Gastric Cancer Through Downregulation of c-Src-PI3K-ERK Pathway

Abstract

Background: Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), a co-activator of estrogen receptors alpha, was confirmed to be directly associated with the oncogenic process of multiple cancers, especially hormone-dependent cancers. The purpose of our research was to explore the biological function, clinical significance, and therapeutic targeted value of PELP1 in gastric cancer (GC). Methods: The expression status of PELP1 in GC cell lines or tissues was analyzed through bioinformatics data mining. Thirty-six GC tissue chip was applied to demonstrate the results of bioinformatics data mining assayed by immunohistochemical method. The expression status of PELP1 in GC cell lines was also analyzed using western blot. Correlation analysis between PELP1 expression and clinicopathological parameter was performed. Kaplan-Meier survival analysis was applied to analyze the relationship between PELP1 expression and total survival time. Three pairs of siRNA were designed to silence the expression of PELP1 in GC. After PELP1 was silenced by siRNA or activated by saRNA, the growth, plate colony formation, migration and invasion ability of the GC cell or normal gastric epithelium cell line was tested in vitro. Cell cycle was tested by flow cytometry. Nude mice xenograft experiment was performed after PELP1 was silenced. The downstream molecular pathway regulated by PELP1 was explored. Molecular docking tool was applied to combine chlorpromazine with PELP1. The inhibitory effect of chlorpromazine in GC was assayed, then it was tested whether PELP1 was a therapeutic target of chlorpromazine in GC. Results: PELP1 expression was elevated in GC cell lines and clinical GC tissue samples. PELP1 silence by siRNA compromised the malignant traits of GC. PELP1 expression positively correlated with tumor invasion depth, lymph node metastasis, tissue grade, TNM stage, but had no correlation with patient age, sex, tumor size, and tumor numbers. Kaplan-Meier survival analysis revealed high PELP1 expression had a shorter survival period in GC patients after follow-up. Q-PCR and western blot revealed PELP1 suppression in GC decreased expression of the c-Src-PI3K-ERK pathway. It was also implied that chlorpromazine (CPZ) can inhibit the malignant traits of GC and downregulate the expression of PELP1. Yan et al. PELP1 Is an Oncogene in Gastric Cancer Conclusions: In a word, PELP1 is an oncogene in gastric cancer and c-Src-PI3K-ERK pathway activation may be responsible for its tumorigenesis, PELP1 may be a potential therapeutic target of chlorpromazine in GC.

Melatonin alleviates valproic acid-induced neural tube defects by modulating Src/PI3K/ERK signaling and oxidative stress

“…The Src/PI3K/ERK signaling pathway has been intricately associated with cell proliferation [57] . Inhibition of phosphorylated ERK1/2/MAPK, known for its role in cell proliferation, has been linked to hyperthermia-induced NTDs [58] .…”

Study of FOXO1-interacting proteins using TurboID-based proximity labeling technology

“…FOXO-regulated genes mainly include those that regulate the cell cycle and cellular death, autophagy, metabolism, and antioxidative processes. FOXO, as a switch that regulates a large class of functional genes, is an important research object in medical biology and life science [ 27 , 28 ]. Cell lines that stably express FOXO can provide a reliable platform to study this family.…”

Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 Promotes Carcinogenesis of Gastric Cancer and Anti-CEACAM6 Fluorescent Probe Can Diagnose the Precancerous Lesions

“…Studies found Src/PI3K/Akt signaling pathway activation is responsible for the GC tumorigenesis (15,16), furthermore, the western-blot was applied to study the roles of CEACAM6 in proteins of Src/PI3K signaling pathway, with the results showing that CEACEM6 over expression can up regulate the expression of p-Src, p-PI3K, p-Akt and MMP9 proteins in the AGS and MKN-45 cells, however, when the Src was inhibited, the down regulation of p-PI3K, p-Akt and MMP9 cannot be recovered by CEACAM6 (Figure 3D). It was speculated that CEACAM6 can accelerate the GC tumorigenesis and progression by Src/PI3K/ Akt signaling pathway (Figure 3E).…”